The hormonal transition your doctor probably isn't talking about — and what it means for your insulin, your CGM, and your life.
Six hormones govern the menopausal transition. Every one of them affects insulin. Tap any card to learn more.
The primary estrogen during reproductive years. It enhances insulin sensitivity in muscle, liver, and fat tissue. As it drops, insulin resistance rises.
Normal premenopausal range: 30–400 pg/mL, dropping below 30 pg/mL in postmenopause. Estradiol binds receptors in muscle tissue to boost glucose uptake. It modulates liver glucose production and promotes subcutaneous (rather than visceral) fat storage. When it falls, a woman who needed 1 unit per 10g of carbohydrate may now need 1.5–2 units for the same meal.
Opposes estrogen and impairs insulin sensitivity. This is why many T1D women needed more insulin in the second half of their cycle. It drops early in perimenopause.
Produced after ovulation by the corpus luteum. In perimenopause, ovulation becomes erratic — progesterone may be absent, low, or unpredictably high from cycle to cycle. The pattern women relied on for insulin adjustments disappears. Early decline also leads to relative "estrogen dominance" and contributes to anxiety, sleep disruption, and mood changes.
Rises as the ovaries lose responsiveness. One of the first measurable signs of perimenopause — but a single test can be misleading.
In early perimenopause, FSH surges can actually drive the ovaries to produce more estrogen than normal. That's why a high FSH doesn't mean low estrogen — and a single blood test during perimenopause can be unreliable for diagnosis. Menstrual history is more diagnostic than a single hormone level during the transition.
Works with FSH to trigger ovulation. Rises during perimenopause as the pituitary tries harder to stimulate ovaries that no longer respond.
Think of it this way: the pituitary gland is shouting at ovaries that can no longer hear it. This overcompensation is what drives many of the hormonal extremes of perimenopause. LH eventually stabilizes at persistently high levels in postmenopause.
Women produce it too — it supports muscle mass, mood, energy, and insulin sensitivity. It begins declining in the 20s and continues through menopause.
Produced by the ovaries (~25%), adrenal glands (~25%), and peripheral conversion of androstenedione. Low testosterone contributes to increased insulin resistance. Its loss compounds with estrogen loss: less muscle mass, higher resistance, harder glucose management. An often-overlooked piece of the metabolic puzzle.
The stress hormone. When progesterone falls, cortisol rises. Sleep disruption from night sweats drives it higher — and every bit of it raises blood sugar.
Progesterone normally counteracts cortisol. Without it, cortisol exposure increases. Sleep disruption from hot flashes and night sweats compounds the problem: poor sleep → elevated cortisol → elevated morning glucose → harder management. Anxiety and mood changes trigger further cortisol release. This isn't a comfort issue — it's a metabolic one.
Menopause isn't a single event — it's a multi-year journey. Here's what each phase means for your T1D management.
They share nearly identical symptoms. This isn't just confusing — it's a safety concern. Here's the overlap and the protocol.
Hypoglycemia can trigger hot flashes, and hot flashes can mask lows. Both can happen simultaneously. Here's the rule:
Check your CGM or blood glucose immediately. Don't guess. Real-time data resolves the confusion in seconds.
If glucose is low, treat the hypo first. Hot flashes can wait. Hypoglycemia cannot.
If glucose is normal, it's likely a hot flash. The moment will pass. But now you have data — and data builds patterns over time.
Menopause symptoms aren't just quality-of-life issues — they're metabolic management issues.
Disrupted sleep → elevated cortisol → elevated morning glucose. Research shows poor sleep quality correlates with larger post-meal spikes the following day. Addressing night sweats isn't comfort — it's metabolic strategy.
Ep 560 Variables: Sleep — Cortisol, circadian rhythm, overnight patternsEstrogen influences serotonin and GABA. Anxiety and stress directly raise blood sugar through cortisol. A woman who runs more anxious during perimenopause will often run higher — and it can look like worsening adherence when it's hormonal.
Ep 1351 Experiencing Chronic Sorrow — Caregiver Burnout series: the emotional weight of chronic illness Ep 840 Managing Burdens — Recognizing when you're carrying too muchReduced concentration and memory lapses are common. T1D management is cognitively demanding — tracking trends, calculating doses, recognizing patterns all require cognitive resources that perimenopause may reduce. This is a genuine management barrier.
Ep 1363 Nighttime Sleep Disturbances — Burnout series: sleep disruption and cognitive loadEstrogen decline shifts fat from hips to abdomen. Visceral fat produces inflammatory cytokines that worsen insulin resistance. Muscle loss from aging and testosterone decline further reduces metabolic capacity. A reinforcing cycle.
Pro Tip 1447 Insulin Resistance — The resistance-weight cycle and how to break itYou can't stop the hormonal transition — but you can meet it with tools, data, and a proactive plan.
This is not a set-it-and-forget-it period. Your settings will need adjustment — and that's normal.
A ratio of 1:10 may need to shift to 1:6.5–1:7 during periods of high insulin resistance. The old ratio isn't wrong — it just doesn't fit the new hormonal environment.
Ep 821 Math Behind ICR — The 500 rule and how to recalculateCorrection doses that reliably brought blood sugar down may no longer be adequate. You may need to increase correction strength.
Ep 822 Math Behind ISF — The 1800 rule and how to test itBackground insulin needs may increase during perimenopause then decrease in postmenopause. AID systems try to compensate but need accurate settings to work well.
Pro Tip 1010 Setting Basal — Overnight testing protocol for recalibrating Pro Tip 1004 Temp Basal — Day-to-day hormonal adjustment toolA simple log in your notes app — correlating with CGM data — can reveal patterns even when things feel chaotic. Check off what you're tracking:
Resistance and weight-bearing exercise builds muscle, which absorbs glucose and directly counters insulin resistance. It also protects bone density — critical for T1D women. Walking after meals continues to help glucose levels.
Pro Tip 1011 Exercise — Aerobic vs. anaerobic, timing, preventing exercise lowsSleep is a diabetes management tool. Cooling the bedroom, HRT for night sweats, timing alcohol avoidance, and exercise timing all improve sleep quality — and by extension, glucose.
Ep 560 Diabetes Variables: Sleep — Cortisol, circadian rhythm, and the feet-on-the-floor effect Ep 596 Diabetes Variables: Alcohol — How alcohol worsens hot flashes and overnight glucoseThis isn't a soft recommendation — it's mechanistic. Cortisol directly raises blood sugar through liver glucose output. Reducing stress has direct, measurable glucose management implications.
Ep 540 Diabetes Variables: Stress — How cortisol drives resistance and the temp basal strategy Ep 840 Managing Burdens — Recognizing emotional overload and finding safe people to share it withThere is very limited research specifically on HRT and T1D. But here's what the available evidence and clinical practice tell us. Explore by topic.
HRT is not contraindicated by Type 1 diabetes. Yet many women with T1D are still told they can't or shouldn't use it without individualized discussion. The old narrative from the 2002 Women's Health Initiative applied to older women, synthetic progestins, and specific risk profiles.
Modern body-identical, transdermal HRT is significantly safer. A 2024 meta-analysis of 17 RCTs with over 29,000 participants found that hormone therapy significantly reduced insulin resistance in healthy postmenopausal women. In T2D populations, HRT reduced HbA1c and fasting glucose in multiple studies.
Women who start HRT during the menopausal transition may find their insulin sensitivity improves — meaning they could need less insulin after starting.
Important Individual responses vary. Some women see significant glucose improvement; others see little change. Monitoring is essential.
Both T1D and menopause independently raise certain long-term risks. Together, they create a compounded profile that demands proactive monitoring.
Proactive steps to manage the compounded risk profile:
Most providers have little training in the intersection of T1D and menopause. These questions help you lead the conversation. Tap any category to expand.
• Can you explain how estrogen and progesterone affect insulin sensitivity, and what happens when they decline?
• At what point in the menopause transition should I expect changes in my insulin needs?
• Why is perimenopause often harder to manage than actual menopause?
• My blood sugar has become less predictable — what's the first thing you'd look at?
• How often should I expect to need to adjust my settings during perimenopause?
• What should I be tracking beyond CGM data to help make sense of what's happening?
• How serious is the confusion between hot flashes and hypoglycemia, and what protocol do you recommend?
• Is there evidence that hypoglycemia can trigger hot flashes — or vice versa?
• Is HRT an option for me given my T1D? Are there specific contraindications?
• What form of HRT is most appropriate — oral, transdermal, other?
• Does the choice of progestogen matter for my glucose management?
• Should I expect my insulin needs to change after starting? In which direction?
• Is there a "window of opportunity" for starting HRT that applies to me?
• How concerned should I be about bone density, and when should I get a DXA scan?
• Given T1D's cardiovascular risk, what does menopause add, and how do you manage that?
• What's your approach to genitourinary symptoms in someone who may also have neuropathy?
Endocrinologists often defer menopause questions to GYN. GYN defers insulin management to endo. Neither team manages the intersection — and you fall through the gap.
• Ask both: "Who is responsible for managing the intersection of my menopause and my diabetes?"
• Consider asking for a coordinated visit or shared notes between providers.
• Ask if either provider has specific experience with T1D and menopause — if not, a menopause specialist (NAMS-certified) may be a valuable addition to your team.
There is almost no research specifically on Type 1 diabetes and menopause. The women navigating this transition are doing so without a roadmap — and often without providers who understand the intersection.
The system didn't prepare you for this. The job of this resource is to give you the framework the clinical world hasn't provided — what to expect, why it's happening, what tools help, and what questions to bring to your doctor.